Which Probiotics Should I Take? A Practical Guide for Family Physicians
Am Fam Physician. 2017 Aug 1;96(3):156.
Which probiotics should I take? We have all heard this question from our patients in clinical practice. In 2012, approximately 3.8 million adults1 and 300,000 children2 were using probiotics—a fourfold increase over the previous five years. This question begets many further clinical questions: Which manufacturer? Which species or strain? For which clinical condition? Improved understanding of the roles of the gut microbiome in health and disease has brought probiotics to the forefront of clinical practice.3 Each probiotic provides a transient microbiome that may confer a health benefit to the host by modifying the gut microenvironment.4 Probiotics do not reinoculate the gut microbiome and are recoverable only in stool samples for one to two weeks.5 Probiotic foods such as yogurt are therefore as effective as supplements in providing an ongoing delivery mechanism.
In this issue, Wilkins and Sequoia present the clinical evidence of probiotics for the treatment of gastrointestinal conditions in infants, children, and adults.6 This article reviews the literature and offers practical information on the studied products (species and strain), as well as third-party tested products.
According to the Dietary Supplement Health and Education Act (DSHEA) of 1994,7 nutritional supplements, including probiotics, are considered food rather than drugs. They are not regulated for clinical application, which results in so-called health claims rather than disease-based claims. The DSHEA requires that dietary supplements meet current good manufacturing practices, but unfortunately, there are substandard products that meet this threshold.
How do we determine a quality standard for the probiotics that we recommend to our patients? Assuring them that products meet DSHEA standards and are generally recognized as safe is necessary but not sufficient. Some physicians avoid over-the-counter probiotics and order from nutritional supplement companies that sell high-quality products only to licensed professionals. These manufacturers provide quality-control data that include an expiration date and number of viable colony-forming units at expiration as assurances of the probiotic viability throughout the lifespan of the product.
In my practice, I recommend probiotics in varying combinations and dosages. Studies show that specific probiotic species or strains demonstrate specific clinical effects. There is good evidence supporting the effectiveness of probiotics for the treatment of irritable bowel syndrome and ulcerative colitis.8,9 Importantly, there is compelling news about the benefit of probiotics for the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile–associated diarrhea.10 These data have changed my antibiotic prescribing practices to include the probiotic Saccharomyces boulardii because it is not eradicated by antibiotics.
When recommending probiotics, check for the National Science Foundation's certification of good manufacturing practice (http://www.nsf.org/regulatory/regulator-nsf-certification). Use the specific probiotic species and strains that have been studied.6 I always make sure that the product states that the dosage recommended is viable at the expiration date, and that the expiration date is printed on the bottle. When these requirements have been met, I know that I am offering my patients the highest quality of probiotics to help prevent and treat disease.
REFERENCESshow all references
1. Clarke TC, et al. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report. 2015; (79):1–16....
2. Black LI, et al. Use of complementary health approaches among children aged 4–17 years in the United States: National Health Interview Survey, 2007–2012. Natl Health Stat Report. 2015;(78):1–19.
3. Sanders ME. Clinical use of probiotics: what physicians need to know. Am Fam Physician. 2008;78(9):1026.
4. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
5. Hütt P, et al. Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults. Benef Microbes. 2011;2(1):79–90.
6. Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170–178.
7. National Institutes of Health. Office of Dietary Supplements. Dietary Supplement Health and Education Act of 1994. https://ods.od.nih.gov/About/DSHEA_Wording.aspx. Accessed May 2, 2017.
8. Quigley EM. Probiotics in irritable bowel syndrome: the science and the evidence. J Clin Gastroenterol. 2015;49(suppl 1):S60–S64.
9. Derikx LA, Dieleman LA, Hoentjen F. Probiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016;30(1):55–71.
10. Shan LS, Hou P, Wang ZJ, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes. 2013;4(4):329–334.
Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Jun 15, 2021
Access the latest issue of American Family Physician